Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study ; volume:29 ; number:1 ; day:14 ; month:11 ; year:2023 ; pages:27-35 ; date:1.2024
International journal of clinical oncology ; 29, Heft 1 (14.11.2023), 27-35, 1.2024
- Urheber
-
Shitara, Kohei
Yamaguchi, Kensei
Muro, Kei
Yasui, Hisateru
Sakai, Daisuke
Oshima, Takashi
Fujimura, Masahiro
Sato, Yuta
Yamazaki, Shunsuke
Wakabayashi, Tatsuya
Sugihara, Masahiro
Kamio, Takahiro
Shoji, Hirokazu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-023-02422-x
- URN
-
urn:nbn:de:101:1-2024031814162931055644
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shitara, Kohei
- Yamaguchi, Kensei
- Muro, Kei
- Yasui, Hisateru
- Sakai, Daisuke
- Oshima, Takashi
- Fujimura, Masahiro
- Sato, Yuta
- Yamazaki, Shunsuke
- Wakabayashi, Tatsuya
- Sugihara, Masahiro
- Kamio, Takahiro
- Shoji, Hirokazu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer